Profile: Dhara Shah

Dhara Shah
Dhara N. Shah, Pharm.D.
Clinical Assistant Professor
Department of Clinical Sciences & Administration
University of Houston College of Pharmacy
Texas Medical Center Campus, Room 223
1441 Moursund Street
Houston, TX 77030

Phone: 832-842-8346
Fax: 832-842-8383
dnshah@central.uh.edu

Education and Post-graduate Training

Doctor of Pharmacy, Summa Cum Laude, University of Houston College of Pharmacy, Houston, Texas

Clinical Research Curriculum, University of Texas Medical School, Houston, Texas, 2009 - present

15th Annual Fellows Course in Hospital Epidemiology and Infection Control, July 6–8, 2011, Johns Hopkins University, Baltimore, Maryland

Infectious Diseases Fellow, University of Houston-College of Pharmacy, Houston, Texas, Mentors: Kevin W. Garey, Pharm.D., M.S., and Herbert L. DuPont, M.D.

PGY-1 Pharmacy Practice Resident, Memorial Hermann-Texas Medical Center, Houston, Texas, Program Director: Bradley Domonoske, Pharm.D., BCPS

Research Interests

Patient-oriented clinical and translational research in the areas of healthcare associated infections and enteric diseases, including:

  • Antibiotic-associated diarrhea
  • Clostridium difficile infection
  • Candida infections

Selected Peer-Reviewed Publications

Jardin CG, Palmer HR, Shah DN, Le F, Beyda ND, Jiang Z, Garey KW. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Jul 5. doi:pii: S0195-6701(13)00187-4. 10.1016/j.jhin.2013.04.017. [Epub ahead of print]

Shah DN, Bhatt NS, Welch JK, Koo HL, Garey KW. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr;83(4):294-9. doi: 10.1016/j.jhin.2012.12.011. Epub 2013 Feb 20.

Beyda ND, Chuang SH, Alam MJ, Shah DN, Ng TM, McCaskey L, Garey KW. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb;68(2):438-43. doi: 10.1093/jac/dks388. Epub 2012 Oct 19. Review.

Le F, Arora V, Shah DN, Salazar M, Palmer HR, Garey KW.  A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: Implications for antibiotic stewardship programs.  Pharmacother. 2012;32(2):129-134.

Tran TT, Palmer HP, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose optimization protocol: A potential policy for antibiotic stewardship programs. Am J Health Syst Pharm. 2012 Jun 1;69(11):979-84.

Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, Garey KW. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun;56(6):3239-43.

Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011; 66(9):2146-51.

Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, DuPont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011; 66(12):2850-5.

Halton K, Arora V, Singh V, Ghantoji SS, Shah DN, Garey KW. Bacterial Colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent. Clin Microbiol Infect. 2011; 17(6):868-9.

Hirsch EB, Cottreau JM, Ikwuagwu JO, Lusardi K, Mohr JF, Rodriguez SM, Shah DN, Tran TT. Significant publications on infectious diseases pharmacotherapy in 2010. Am J Health Syst Pharm. 2011; 68(21):2075-85.

Shah D, Dang MDQ, Hasbun R, Koo HL, Jiang ZD, DuPont HL, and Garey KW. Clostridium difficile infection - An update on emerging antibiotic treatment options and antibiotic resistance. Exp Rev Anti-infect Ther. 2010; 8(5):555-64.

Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Annals of Pharmacotherapy. 2008; 42(6):827-35.

Hendley R, Laegeler A, Clowe J, Shah D, Shields R, Stewart B. Preliminary 2006 comparison of Medicare Part D prescription drug plans. TSHP Journal. 2006; 7(2):6-11. 

Abstracts and Presentations

Grimes CZ, Shah DN, Koo HL, DuPont HL. Validity of recommended criteria for attributable mortality associated with Clostridium difficile Infection. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Garey KW, Shah DN, Habib M, Lasco T. Clinical assessment of nanotechnology and miniaturized magnetic resonance to detect candidemia in hospitalized patients. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Shah DN, Koo HL, Lasco TM, Palmer HR, Garey KW. Assessment of attributable mortality rate of candidemia in candidemia pts with inpatient mortality. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

Shah DN, Dima-ala A, Dolormente K, Arora V, Garey KW. Incidence of antibiotic-associated diarrhea in hospitalized patients given broad spectrum antibiotics. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

Shah DN, Yau R, Weston J, Lasco T, Salazar M, Palmer H, Garey KW. Pre-exposure to antifungals as a risk factor for fluconazole-non-susceptible Candida species in hospitalised patients with candidemia. 21st ECCMID/27th ICC meeting, Milan, Italy. May 7-10, 2011.

Santimaleeworagun W, Christensen J, Singh V, Shah DN, Chang KT ,Tam VH, Garey KW Molecular epidemiology of Clostridium difficile and prevalence of the NAP-1strain among patients admitted to a general and a private hospital in Houston, Texas USA. 21st ECCMID/27th ICC meeting, Milan, Italy. May 7-10, 2011.

Garey KW, Ghantoji S, Shah D, Habib M, Arora V, Jiang ZD, DuPont H. A randomised, double-blind, placebo-controlled pilot study to assess the effect of rifaximin “chaser” to prevent recurrent diarrhoea in patients with Clostridium difficile infection. 21st ECCMID/27th ICC meeting, Milan, Italy. May 7-10, 2011.

Xu R, Salazar M, Weston JS, Shah DN, Putney KS, Garey KW. Susceptibility of Candida species in patients with candidemia. SCCM’s 40th Critical Care Congress, San Diego, CA. January 16-18, 2011.

De La Cabada J, Jiang Z-D, Ghantoji SS, Garey KW, Lasco TM, Larocco M, Shah D, DuPont HL. Fecal lactoferrin in Clostridium difficile infection as a predictor of single bouts vs. recurrent disease. IDSA 48th Annual Meeting, Vancouver, Canada. October 21-24, 2010 (ORAL).

Shah DN, Yau RW, Weston J, Lasco T, Salazar M, Palmer H, Garey KW. Utility of fluconazole as de-escalation therapy in patients with fluconazole-susceptible candidemia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010 (ORAL).

Gordon SM, Shah DN, Tran TC, Lasco T, Garey KW. Variations in time to blood culture positivity stratified by Candida species and fluconazole susceptibility. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Daptomycin dose-effect relationship against vancomycin-resistant enterococcal bacteremia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Shah DN, Yau RW, Weston J, Xu R, Salazar M, Palmer H, Garey KW. Changes to empiric antifungal therapy based on susceptibility testing results. 50th ICAAC, Boston, MA. Sept. 12-15, 2010.

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Evaluation of daptomycin PK/PD dose optimization protocol. 50th ICAAC, Boston, MA. Sept. 12-15, 2010 (ORAL).

Xu R, Weston JS, Salazar M, Shah DN, Garey KW. Susceptibility and recurrence of Candida species before and after a formulary change from caspofungin to micafungin in patients with candidemia. 44th ASHP Midyear Meeting, Las Vegas, NV. Dec. 5-10.

Awards and Honors

  • ICAAC Infectious Diseases Fellows Grant, American Society of Microbiology, 2010, 2011
  • Best Resident/Fellow Poster Winner, American College of Clinical Pharmacy, 2010
  • Special Recognition Award: Excellence in Clinical Skills, University of Houston College of Pharmacy, 2008
  • Golden Key International Honor Society, University of Houston, 2007
  • Rho Chi Pharmaceutical Honor Society, University of Houston College of Pharmacy, 2006
  • Sandra Evans Webb Scholarship, TSHP R&E Foundation, 2007 – 2008

Memberships

  • Infectious Diseases Society of America, 2011 – present
  • American College of Clinical Pharmacy, 2010 – present
  • The Society of Infectious Disease Pharmacists, 2010 – present
  • American Society for Microbiology, 2009 – present

CV